{"id":9922,"date":"2024-05-21T02:52:38","date_gmt":"2024-05-21T02:52:38","guid":{"rendered":"https:\/\/economicherald.net\/?p=9922"},"modified":"2024-05-21T02:52:38","modified_gmt":"2024-05-21T02:52:38","slug":"asx-health-stocks-telix-says-tlx592-shows-promise-in-prostate-cancer-battle","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=9922","title":{"rendered":"ASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battle"},"content":{"rendered":"<p>Telix says TLX592 is effective on prostate cancer<\/p>\n<p><a href=\"https:\/\/stockhead.com.au\/company\/telix-pharmaceuticals-tlx\/\">Telix Pharmaceuticals (ASX:TLX)<\/a> has today announced the successful completion of CUPID, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer.<\/p>\n<p>The CUPID study is an investigation employing a \u201c3+3 mass dose escalation design\u201d across four patient cohorts.<\/p>\n<p>Its aim is to assess the safety, tolerability, pharmacokinetics, biodistribution, and radiation dosimetry of its drug, TLX592.<\/p>\n<p>The study utilises copper-64 (64Cu) \u2013 detectable via Positron Emission Tomography (PET) \u2013 which serves as a surrogate for actinium-225.<\/p>\n<p>Preliminary findings from the study, involving 11 assessable patients, have unveiled expedited blood kinetics compared to its lead radiopharma antibody-drug, <strong>TLX591<\/strong>.<\/p>\n<p>Faster blood kinetics mean that the drug is absorbed and circulated more rapidly in the bloodstream. This efficiency can potentially lead to quicker onset of action and therapeutic effects.<\/p>\n<p>Moreover, TLX592 demonstrates comparable on-target and off-target bio-distribution, alongside favourable hepatic clearance (the process by which drugs or substances are removed from the bloodstream by the liver).<\/p>\n<p>Encouragingly, no serious adverse events have been reported during the course of the study.<\/p>\n<p>Based on these results, Telix is planning to move forward with TLX592 into a Phase I\/II study using 225Ac later in 2024, if it gets the thumbs-up from the regulators.<\/p>\n<p>Telix says TLX592 further deepens its PSMA2-targeting prostate cancer therapy portfolio, joining its main player, TLX591, which is already making good progress in the <em>ProstACT GLOBAL Phase III<\/em> study.<\/p>\n<p>\u201cWe are excited to progress TLX592 into therapeutic studies where our aim is to develop this agent for both early metastatic prostate cancer and late-stage patients who are no longer responding to lutetium therapy,\u201d said Dr David N. Cade, group chief medical officer at Telix.<\/p>\n<p>\u00a0<\/p>\n<h2>Sonic updates forecast<\/h2>\n<p>Giant healthcare stock <strong><a href=\"https:\/\/stockhead.com.au\/company\/sonic-healthcare-shl\/\">Sonic Healthcare (ASX:SHL)<\/a><\/strong> meanwhile tumbled by -8.5% this morning after downgrading its forecast.<\/p>\n<p>Sonic said it is now forecasting (with two months\u2019 trading outstanding) EBITDA for FY24 of approximately $1.6 billion, on revenues of approximately $8.9 billion.<\/p>\n<p>Guidance for FY25 will be updated at its full year results\u2019 release in August.<\/p>\n<p>Although organic revenue growth has been holding strong at 6% for the four months leading up to April 30th, SHL\u2019s profit growth hasn\u2019t quite hit the mark.<\/p>\n<p>This is partially due to inflationary pressures impacting operations, the company says, compounded by unfavourable currency exchange rates.<\/p>\n<p>Additionally, several initiatives aimed at improving margins in the second half of FY24 have encountered delays, impacting anticipated earnings growth until FY25.<\/p>\n<p>Looking ahead however, Sonic anticipates a moderation of inflationary pressures, with headline inflation rates in Sonic\u2019s key markets already showing signs of reduction to a range of 1.4% to 3.6%.<\/p>\n<p>\u00a0<\/p>\n<h2>Share prices today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span>\u00a0<br \/>\n<span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-telix-says-tlx592-shows-promise-in-prostate-cancer-battle\/\">ASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battle<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Telix says TLX592 is effective on prostate cancer Telix Pharmaceuticals (ASX:TLX) has today announced the successful completion of CUPID, a first-in-human Phase I dose escalation <a href=\"https:\/\/economicherald.net\/?p=9922\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":9923,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-9922","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battle - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=9922\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battle - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Telix says TLX592 is effective on prostate cancer Telix Pharmaceuticals (ASX:TLX) has today announced the successful completion of CUPID, a first-in-human Phase I dose escalation [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=9922\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-21T02:52:38+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=9922#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=9922\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battle\",\"datePublished\":\"2024-05-21T02:52:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=9922\"},\"wordCount\":467,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=9922#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Telix-says-TLX592-shows-promise-in-prostate-cancer-battle.-Picture-Getty-bTd1fZ.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=9922\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=9922\",\"name\":\"ASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battle - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=9922#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=9922#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Telix-says-TLX592-shows-promise-in-prostate-cancer-battle.-Picture-Getty-bTd1fZ.jpeg\",\"datePublished\":\"2024-05-21T02:52:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=9922#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=9922\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=9922#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Telix-says-TLX592-shows-promise-in-prostate-cancer-battle.-Picture-Getty-bTd1fZ.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Telix-says-TLX592-shows-promise-in-prostate-cancer-battle.-Picture-Getty-bTd1fZ.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=9922#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battle\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battle - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=9922","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battle - Economic Herald","og_description":"Telix says TLX592 is effective on prostate cancer Telix Pharmaceuticals (ASX:TLX) has today announced the successful completion of CUPID, a first-in-human Phase I dose escalation [more...]","og_url":"https:\/\/economicherald.net\/?p=9922","og_site_name":"Economic Herald","article_published_time":"2024-05-21T02:52:38+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=9922#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=9922"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battle","datePublished":"2024-05-21T02:52:38+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=9922"},"wordCount":467,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=9922#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/05\/Telix-says-TLX592-shows-promise-in-prostate-cancer-battle.-Picture-Getty-bTd1fZ.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=9922","url":"https:\/\/economicherald.net\/?p=9922","name":"ASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battle - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=9922#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=9922#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/05\/Telix-says-TLX592-shows-promise-in-prostate-cancer-battle.-Picture-Getty-bTd1fZ.jpeg","datePublished":"2024-05-21T02:52:38+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=9922#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=9922"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=9922#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/05\/Telix-says-TLX592-shows-promise-in-prostate-cancer-battle.-Picture-Getty-bTd1fZ.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/05\/Telix-says-TLX592-shows-promise-in-prostate-cancer-battle.-Picture-Getty-bTd1fZ.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=9922#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Telix says TLX592 shows promise in prostate cancer battle"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/9922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9922"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/9922\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/9923"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}